Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANEB Anebulo Pharmaceuticals	$2.60 +5.7%	$2.11	$0.80 ▼ $3.42	$106.82M	-0.88	151,582 shs	211,831 shs
AQST Aquestive Therapeutics	$3.98 +1.8%	$3.82	$2.12 ▼ $5.80	$396.90M	1.99	1.30 million shs	1.13 million shs
RGNX REGENXBIO	$9.01 +11.1%	$8.52	$5.03 ▼ $13.48	$455.13M	1.11	680,725 shs	1.36 million shs
YMAB Y-mAbs Therapeutics	$8.53	$5.66	$3.55 ▼ $16.11	$387.59M	0.57	1.96 million shs	573,836 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANEB Anebulo Pharmaceuticals	0.00%	+4.00%	-19.75%	+132.14%	+30.00%
AQST Aquestive Therapeutics	0.00%	-3.16%	-5.24%	+69.36%	-14.41%
RGNX REGENXBIO	0.00%	+2.15%	-1.31%	-7.21%	-26.21%
YMAB Y-mAbs Therapeutics	0.00%	+0.12%	+76.24%	+97.45%	-38.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANEB Anebulo Pharmaceuticals	2.1718 of 5 stars	3.3	3.0	0.0	2.5	1.7	0.0
AQST Aquestive Therapeutics	2.2965 of 5 stars	3.4	3.0	0.0	3.9	0.0	0.0
RGNX REGENXBIO	4.3632 of 5 stars	3.4	3.0	4.6	2.3	2.5	0.6
YMAB Y-mAbs Therapeutics	2.0472 of 5 stars	2.9	4.0	0.0	0.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANEB Anebulo Pharmaceuticals	2.50	Moderate Buy	$5.50	111.54% Upside
AQST Aquestive Therapeutics	2.88	Moderate Buy	$10.14	154.85% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$28.38	214.93% Upside
YMAB Y-mAbs Therapeutics	1.80	Reduce	$9.62	12.80% Upside

Current Analyst Ratings Breakdown

Latest ANEB, YMAB, AQST, and RGNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	RGNX REGENXBIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$34.00
8/13/2025	AQST Aquestive Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/8/2025	RGNX REGENXBIO	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $17.00
8/8/2025	RGNX REGENXBIO	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $37.00
8/8/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00
8/6/2025	YMAB Y-mAbs Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$11.00 ➝ $8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$26.00 ➝ $8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/5/2025	YMAB Y-mAbs Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Underperform ➝ Neutral	$8.60

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	$0.15 per share	N/A
AQST Aquestive Therapeutics	$57.56M	6.90	N/A	N/A	($0.73) per share	-5.45
RGNX REGENXBIO	$83.33M	5.46	N/A	N/A	$4.23 per share	2.13
YMAB Y-mAbs Therapeutics	$87.68M	4.42	N/A	N/A	$1.93 per share	4.42

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANEB Anebulo Pharmaceuticals	-$8.20M	-$0.26	N/A	∞	N/A	N/A	-90.11%	-84.53%	9/24/2025 (Estimated)
AQST Aquestive Therapeutics	-$44.14M	-$0.70	N/A	N/A	N/A	-147.38%	N/A	-63.87%	11/3/2025 (Estimated)
RGNX REGENXBIO	-$227.10M	-$3.44	N/A	N/A	N/A	-112.70%	-66.95%	-34.14%	11/5/2025 (Estimated)
YMAB Y-mAbs Therapeutics	-$29.67M	-$0.50	N/A	N/A	N/A	-26.03%	-24.60%	-18.89%	N/A

Latest ANEB, YMAB, AQST, and RGNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	AQST Aquestive Therapeutics	-$0.18	-$0.14	+$0.04	-$0.14	$11.32 million	$10.00 million
8/8/2025	Q2 2025	YMAB Y-mAbs Therapeutics	-$0.27	-$0.07	+$0.20	-$0.07	$18.40 million	$19.52 million
8/7/2025	Q2 2025	RGNX REGENXBIO	-$1.13	-$1.38	-$0.25	-$1.38	$40.87 million	$21.36 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANEB Anebulo Pharmaceuticals	N/A	25.29	25.29
AQST Aquestive Therapeutics	N/A	3.53	3.18
RGNX REGENXBIO	N/A	3.13	3.13
YMAB Y-mAbs Therapeutics	N/A	4.00	3.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANEB Anebulo Pharmaceuticals	28.40%
AQST Aquestive Therapeutics	32.45%
RGNX REGENXBIO	88.08%
YMAB Y-mAbs Therapeutics	70.85%

Insider Ownership

Company	Insider Ownership
ANEB Anebulo Pharmaceuticals	80.60%
AQST Aquestive Therapeutics	8.35%
RGNX REGENXBIO	12.79%
YMAB Y-mAbs Therapeutics	19.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANEB Anebulo Pharmaceuticals	4	41.08 million	7.97 million	Not Optionable
AQST Aquestive Therapeutics	160	99.72 million	91.40 million	Optionable
RGNX REGENXBIO	370	50.51 million	44.05 million	Optionable
YMAB Y-mAbs Therapeutics	150	45.44 million	36.49 million	Optionable

ANEB, YMAB, AQST, and RGNX Headlines

Recent News About These Companies

Y-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB

August 19, 2025 | globenewswire.com

Acquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics Stock

August 13, 2025 | insidermonkey.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Posts Earnings Results, Beats Expectations By $0.20 EPS

August 11, 2025 | marketbeat.com

XTX Topco Ltd Purchases 70,686 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

August 10, 2025 | marketbeat.com

A Look Ahead: Y-mAbs Therapeutics's Earnings Forecast

August 9, 2025 | benzinga.com

Y-mAbs (YMAB) Q2 Revenue Falls 14%

August 9, 2025 | aol.comA

Federated Hermes Inc. Has $680,000 Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

August 9, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates

August 8, 2025 | zacks.com

Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders

August 8, 2025 | businesswire.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Downgraded by Brookline Capital Management to Hold

August 8, 2025 | marketbeat.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Hold" at Cantor Fitzgerald

August 8, 2025 | marketbeat.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Hold" at Truist Financial

August 8, 2025 | marketbeat.com

Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

August 8, 2025 | globenewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)

August 7, 2025 | prnewswire.com

Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB

August 7, 2025 | businesswire.com

HC Wainwright Reiterates "Neutral" Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)

August 7, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. to Report Q2 2025 Financial Results on August 8, 2025, forgoing Earnings Call

August 7, 2025 | quiverquant.comQ

Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

August 7, 2025 | globenewswire.com

HC Wainwright & Co. Downgrades Y-mAbs Therapeutics (YMAB)

August 7, 2025 | msn.com

SERB bets on rare cancer drug in $412 million deal for Y-mAbs

August 6, 2025 | thepharmaletter.comT

Jones Trading Downgrades Y-mAbs Therapeutics (YMAB)

August 6, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANEB, YMAB, AQST, and RGNX Company Descriptions

Anebulo Pharmaceuticals NASDAQ:ANEB

$2.60 +0.14 (+5.69%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.59 -0.01 (-0.35%)

As of 08/22/2025 07:12 PM Eastern

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Aquestive Therapeutics NASDAQ:AQST

$3.98 +0.07 (+1.79%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.00 +0.02 (+0.53%)

As of 08/22/2025 07:55 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

REGENXBIO NASDAQ:RGNX

$9.01 +0.90 (+11.10%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$9.02 +0.01 (+0.11%)

As of 08/22/2025 04:46 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Y-mAbs Therapeutics NASDAQ:YMAB

$8.53 0.00 (0.00%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$8.54 +0.01 (+0.06%)

As of 08/22/2025 06:24 PM Eastern

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time